Taken together, these results demonstrate that composition of our LNP-S60 containing siRNA against c-Rel is non-toxic and efficient enough to inhibit c-Rel in professional phagocytes and therefore could be further tested in preclinical and clinical studies to counteract the development of inflammation, cancers and other autoimmune diseases that mediated by c-Rel. This evidence concerns the gene REL and cancer.